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The Plasmodium falciparum circumsporozoite (CS) protein (CSP) is a major vaccine target for preventing malaria infection.
Thus, developing strong and durable antibody and T cell responses against CSP with novel immunogens and potent adjuvants
may improve upon the success of current approaches. Here, we compare four distinct full-length P. falciparum CS proteins ex-
pressed in Escherichia coli or Pichia pastoris for their ability to induce immunity and protection in mice when administered
with long-chain poly(I·C) [poly(I·C)LC] as an adjuvant. CS proteins expressed in E. coli induced high-titer antibody responses
against the NANP repeat region and potent CSP-specific CD4 T cell responses. Moreover, E. coli-derived CS proteins in combi-
nation with poly(I·C)LC induced potent multifunctional (interleukin 2-positive [IL-2], tumor necrosis factor alpha-positive
[TNF-], gamma interferon-positive [IFN-]) CD4 effector T cell responses in blood, in spleen, and particularly in liver.
Using transgenic Plasmodium berghei expressing the repeat region of P. falciparum CSP [Pb-CS(Pf)], we showed that there was a
1- to 4-log decrease in malaria rRNA in the liver following a high-dose challenge and50% sterilizing protection with a low-
dose challenge compared to control levels. Protection was directly correlated with high-level antibody titers but not CD4 T cell
responses. Finally, protective immunity was also induced using the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-
stable emulsion (GLA-SE) as the adjuvant, which also correlated with high antibody titers yet CD4 T cell immunity that was
significantly less potent than that with poly(I·C)LC. Overall, these data suggest that full-length CS proteins and poly(I·C)LC or
GLA-SE offer a simple vaccine formulation to be used alone or in combination with other vaccines for preventing malaria
infection.
Malaria infection with Plasmodium falciparum causes morethan 600,000 deaths annually aswell as significantmorbidity
worldwide (1). A range of efforts to control and treat malaria
include public health measures such as insecticide-treated bed
nets, indoor residual spraying, and widespread usage of antima-
larial drugs. Despite the impact of these approaches, the most
cost-effective solution to prevent infection and to ultimately con-
trol the malaria endemic is to develop a vaccine.
Currently, themost advanced vaccine tested in humans against
P. falciparum infection is RTS,S, which targets the circumsporo-
zoite (CS) protein (CSP), the major and most abundant antigen
expressed on the surfaces of infectious sporozoites. RTS,S given
with the AS01 adjuvant (RTS,S/AS01) shows 30% protection
against clinical disease and severe malaria (2, 3). Thus, while these
first results in phase III trials with RTS,S/AS01 are encouraging,
there may be additional approaches for further optimizing the
breadth, potency, and duration of immunity against the CSP us-
ing different immunogens or more-potent adjuvants. In terms of
antigen design, RTS,S is comprised of a truncated form of CSP
containing the central repeat region, NANP, which is a target for
antibody-mediated neutralization, as well as CD8 and CD4 T
cell epitopes at the C-terminal end. This truncated CS protein is
then fused to the hepatitis B virus surface antigen, creating an
immunogenic particle. Therefore, using a more-full-length CSP,
including the N-terminal end and the R1 region of CSP as well as
the minor repeat region (NVDP), might favor broader antibody
responses than against the NANP repeat region alone (4–8).
Moreover, a full-length CSP may provide additional T cell
epitopes, leading to increased breadth of cellular immunity, which
could also enhance protection. Another approach is to enhance
the humoral and cellular immune responses by altering the type of
adjuvant given with the full-length-CSP-based protein vaccine.
Early studies in mice showed that protection was associated
with high antibody titers (9–11). The next generation of malaria
vaccines combined CSP with more-potent adjuvants, like Pseu-
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domonas aeruginosa exotoxin A, monophospholipid A (MPL),
mycobacterial cell wall skeleton, or squalene (Detox; Ribi Immu-
nochem) (12–14), which resulted in high antibody titers; how-
ever, they failed to confer sufficient protective efficacy (15–17). In
contrast, studies using irradiated sporozoites for vaccination have
shown a critical requirement for gamma interferon (IFN-) and
cellular immunity in mediating protection against malaria (18,
19). Accordingly, optimizing CD4 T cell-derived IFN- produc-
tion after RTS,S vaccination by altering the adjuvant formulation
enhanced protection (20–22). Using the Toll-like receptor 4
(TLR4) ligand MPL and saponin (QS-21) in an oil-water emul-
sion (AS02) or liposome (AS01Bor -E) formulation led to a strong
antibody response and increased CD4 T cell immunity com-
pared to levels induced with older formulations with alum and
MPL (21, 23, 24). Collectively, these data highlight the importance
of adjuvant formulations in optimizing immunity and protection.
In this study, long-chain poly(I·C) [poly(I·C)LC] and the
TLR4 agonist glucopyranosyl lipid adjuvant-stable emulsion
(GLA-SE) were compared as adjuvants when they were adminis-
tered with a number of CS proteins expressed in the yeast Pichia
pastoris or in Escherichia coli, to which we refer as full length but
which lack the glycosylphosphatidylinositol (GPI) signal region
and contain various numbers of the NANP repeat region.
Poly(I·C)LC is a unique formulation of long-chain double-
stranded RNA, polyinosinic-poly(C), and carboxy methylcellu-
lose that has extended in vivo activity compared to that of
poly(I·C). Poly(I·C)LC mediates innate signaling through TLR3
and melanoma differentiation-associated protein 5 (MDA-5),
leading to activation of dendritic cells and induction of interleukin
12 (IL-12) and type I interferons (IFNs) (25–27). In addition,
poly(I·C) has been shown to promote T cell survival and enhance
germinal-center formation through the generation of CD4 T
follicular helper (Tfh) cells (28). As an immune adjuvant,
poly(I·C)LC has been shown to elicit strong humoral and cellular
immunity when administered with a variety of protein- or den-
dritic cell-targeting vaccines in a number of mouse and nonhu-
man primate (NHP) studies (29–35).
GLA is a synthetic and therefore homogeneous variant of the
TLR4 agonist lipid A, formulated in a stable oil-in-water emulsion
(SE) (36). Strong Th1 immune responses induced by protein an-
tigens in combination with GLA-SE have been observed inmouse
models of tuberculosis (37), leishmaniasis (38), and influenza
(39). Additionally, GLA-SE showed an adjuvant activity similar to
or enhanced relative to that ofMPL-SE (one of the adjuvant com-
ponents in AS01) in various animal models, such as mice, guinea
pigs, and nonhuman primates (40, 41).
Here, we compare four full-length P. falciparum CS proteins
expressed in E. coli or in the yeast P. pastoris given with
poly(I·C)LC or GLA-SE as an adjuvant and determine their rela-
tive immunogenicities and levels of protection using an in vivo
mouse challenge model. Furthermore, one of the CS proteins and
poly(I·C)LC was tested in NHPs. Together, these data provide a
potential simple vaccine formulation for inducing potent and
protective P. falciparum CSP responses.
MATERIALS AND METHODS
Animals. Six- to 8-week-old C57BL/6mice were obtained fromThe Jack-
son Laboratories (Bar Harbor, ME) and maintained in the Vaccine Re-
search Center Animal Care Facility (Bethesda, MD) under pathogen-free
conditions.Male, Indian rhesusmacaqueswere stratified into comparable
groups on the basis of age and weight. The animals were housed at the
School of Medicine, Comparative Medicine and Veterinary Resources,
University ofMaryland. All experiments were conducted according to the
guidelines of the National Research Council under protocols approved by
the Institutional Animal Care and Use Committee at the National Insti-
tutes of Health.
Reagents. Four P. falciparumCS proteins were provided by the PATH
Malaria Vaccine Initiative (MVI; Washington, DC) and provided to us in
a blind manner (they were designated CSP1, CSP2, CSP3, and CSP4).
These four proteins are called full length in the text, but they lack the GPI
signal region and contain various numbers of the repeat region. After the
immune studies were completed, it was revealed to us that two proteins
were expressed in E. coli (CSP1 and CSP2) and two were expressed in P.
pastoris (CSP3 and CSP4). CSP1 and CSP2 were provided to the MVI
from Gennova (Pune, India) and WRAIR (Silver Spring, MD), respec-
tively. Protein concentration was measured using a bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL). Endotoxin contaminants
were determined using the Limulus amebocyte lysate (LAL) assay (Lonza,
Walkersville, MD). If endotoxin levels exceeded 2 endotoxin units (EU)/
ml, endotoxin was removed by two-phase extraction with Triton X-114.
Small amounts of endotoxin was detected in the E. coli-derived proteins.
Thus, all four proteins, including the two expressed in yeast, which had no
detectable endotoxin, were treated with Triton X-114. All proteins used
for immunization had final endotoxin levels below 1 EU/ml. After re-
moval of endotoxin, protein concentration was determined to confirm
that all groups ofmice received the same amount of protein. P. falciparum
CSP15-mer peptides overlapping by 11 amino acids (aa) and spanning the
entire length of the protein (P. falciparum 3D7 strain) were synthesized by
GenScript. Each batch of CSP was tested for accurate size using SDS-
PAGE.
Antibodies. The following anti-mouse antibodies for flow cytometry
were purchased from BD Pharmingen: purified anti-CD28 (37.51),
PerCP–Cy55–anti-CD3 (145-2C11), and Alexa 700–anti-CD4 (RM4-5).
The following antibodies were purchased from BioLegend: allophycocya-
nin (APC)–Cy7–anti-CD8 (53-6.7). LIVE/DEAD fixable violet dead cell
stain (ViViD) were purchased from Molecular Probes, and staining was
performed as described by Perfetto et al. (42). Intracellular staining was
performed according to the BD Cytofix/Cytoperm kit instructions using
APC–anti-IFN- (XMG1.2), phycoerythrin (PE)–Cy7–anti-tumor ne-
crosis factor alpha (anti-TNF-) (MP6-XT22), and PE–anti-IL-2 (MQ1-
17H12), which were purchased from BD Biosciences, and Alexa Fluor
488–anti-IL-10 (JES5-16E3), which was purchased from eBioscience.
For staining of nonhuman primate (NHP) cells, the following anti-
human antibodies were purchased from BD Pharmingen: purified anti-
CD49d (9F10), APC–Cy7–anti-CD3 (SP34-2), PE–Cy7–anti-TNF-
(MAb11), PE–anti-IL-2 (MQ1-17H12), PE–Cy5–anti-CD95 (DX2), and
fluorescein isothiocyanate (FITC)–anti-IFN- (B27). PacificBlue–anti-
CCR7 (TG8/CCR7) was purchased from BioLegend. Anti-CD45RA–R
phycoerythrin-Texas Red (ECD) (clone 2H4LDH11LDB9) was pur-
chased from Beckman Coulter, and Qdot605–anti-CD4 (S3.5) was pur-
chased from Invitrogen. The conjugates Alexa 680–anti-CD28 (CD28.2)
and Qdot655–anti-CD8 (RPA-T8) were produced in-house by the labo-
ratory of Mario Roederer (NIAID, NIH, Bethesda, MD).
Immunizations.C57BL/6micewere immunizedwith 2g or 20g of
CSP,with orwithout 50g poly(I·C)LC (Oncovir, Inc.,Washington,DC)
or 5 g GLA-SE (Infectious Disease Research Institute, Seattle, WA)
which are the optimal doses for these adjuvants. Naive mice or mice im-
munized with the adjuvant alone served as controls. The vaccines were
administered subcutaneously (s.c.) in both hind footpads in a total vol-
ume of 50 l per foot. Animals were immunized at weeks 0 and 3 or 0, 3,
and 6.
Rhesus macaques were immunized with 100 g of P. falciparum CSP
mixed with 1 mg of poly(I·C)LC. A total volume of 1 ml was injected s.c.
into the deltoid area of the upper arm. For boosting, the opposite armwas
used. Animals were immunized at weeks 0, 5, and 16.
Kastenmüller et al.
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Analysis of CD4 T cell responses. Cells from mice were harvested
from spleens at various times postvaccination, and single-cell suspensions
(2  106 cells/well) from individual mice were incubated for 5 h with
anti-CD28, 10 g/ml Brefeldin A, and 2 g/ml CSP peptide pool. Cells
were stained with the viability dye LIVE/DEAD fixable violet dead cell
stain (ViViD), CD4, and CD8, followed by intracellular staining for CD3,
IFN-, IL-2, IL-10, and TNF- using the BD Cytofix/Cytoperm kit ac-
cording to the manufacturer’s instructions. For intrahepatic-lymphocyte
isolation, the liver was perfused with phosphate-buffered saline (PBS)
before being processed, and lymphocytes were isolated by Percoll density
centrifugation. Stimulation and staining were performed as described for
splenocytes in this section.
For analysis of NHP peripheral blood mononuclear cells (PBMCs),
cryopreserved cells were thawed and rested overnight at 37°C. The next
day, cells (2 106 cells/well) were stimulated for 5 hwith anti-CD49d and
anti-CD28, 10 g/ml Brefeldin A, and 2 g/ml CSP peptide pool. Cells
were stained in warm medium with CCR7, followed by surface staining
with a LIVE/DEADfixable aqua dead cell stain kit (Invitrogen), CD45RA,
CD95, CD4, and CD8 in PBS. Intracellular cytokine staining was per-
formed using IFN-, IL-2, CD3, and TNF- with the BD Cytofix/Cy-
toperm kit according to themanufacturer’s instructions. Cells were resus-
pended in 1% paraformaldehyde, acquired on a modified BD LSR II flow
cytometer, and analyzed using FlowJo software (Tree Star), Pestle, and
SPICE (Mario Roederer, NIAID, NIH).
Detection of CSP-specific antibodies. Serum samples from immu-
nized mice and NHPs were analyzed for IgG antibodies specific for the
repeat region ([NANP]6 peptide) of P. falciparum CSP by the Malaria
Serology Laboratory atWRAIR. Plates were read at 414 nm, and endpoint
titers were calculated at an optical density (OD) of 1.0. For analysis of total
CSP-specific IgG1 and IgG2a titers, enzyme-linked immunosorbent assay
(ELISA) plates were coated with CSP1 protein at a concentration of 1
g/ml and washed. Serially diluted serum samples from immunized or
control mice were added in duplicate for 2 h. After being washed, samples
were incubated with either anti-mouse IgG1-horseradish peroxidase
(HRP) or anti-mouse IgG2a-HRP. Plates were then developed with
3,3=,5,5=-tetramethylbenzidine substrate-chromogen (Dako) and read at
450 nm. Midpoint 50% effective concentration (EC50) titers were calcu-
lated using 4PL curve fitting.
Immunofluorescent antibody (IFA) assay. To determine whether se-
rumbound to sporozoites, slides (Tekdon Inc.; poly-L-lysine coated) were
coated with a 10-l suspension of sporozoites of P. berghei expressing the
repeat region of CSP from P. falciparum [Pb-CS(Pf)] at a concentration of
4  105 to 6  105 sporozoites/ml and air dried. Serum samples from
immunizedmice orNHPswere diluted in PBS-1%bovine serum albumin
(BSA) prior to their addition to the slides (10 l of sample) and then
incubated for 30 min at room temperature. Slides were then washed with
PBS-1% BSA, and 10 l of a secondary-antibody solution [Alexa Fluor
488 F(ab=)2 fragment of goat anti-mouse IgG(HL) (2 g/ml; Invitro-
gen) and FITC-labeled goat anti-monkey IgG(HL) (KPL) for mice and
NHPs, respectively] was added for 30 min at room temperature; then
slides were washed with PBS-1% BSA. Fluorescent sporozoites were visu-
alized using an upright fluorescence microscope (Nikon Eclipse 90i). The
lowest titer at which sporozoites were visualized was scored as positive.
Binding of serum antibodies to sporozoites was scored as  (very
good), (good), (weak), or (no) binding.
Sporozoite challenge. Mice were challenged intravenously (i.v.) with
1.5 104 transgenic Pb-CS(Pf) sporozoites, kindly provided by E. Nardin
(10). Approximately 40 h later, mice were euthanized to assess parasite
burden in livers. Parasite loads were determined by quantitative PCR
(qPCR) for P. berghei 18S rRNA (43). For the assessment of blood-stage
parasitemia, mice were challenged i.v. with 1  103 of the transgenic
Pb-CS(Pf) sporozoites. Starting on day 4, blood smears were taken and
observed under a microscope. Smears were fixed withmethanol (for 30 s)
before being stained with a 10% Giemsa stain solution (Sigma-Aldrich)
for 15 min.
Serum transfer. Serum was collected from individual mice 2 weeks
after three immunizations with 20 g CSP1 and poly(I·C)LC, and 0.5 ml
was transferred i.v. immediately prior to challenge.
Isolation of PBMCs from NHPs. PBMCs were isolated from fresh
blood by Ficoll density centrifugation using LeucoSep tubes (Greiner Bio
FIG 1 Graphic diagrams of the characteristics of four different CSPs. Full-length CSP consists of the signal peptide (SP), two highly conserved motifs at the N-
andC-terminal ends of the protein, region 1 and region 2 plus (R1 andR2), tandem repeats (37NANP repeats), and theGPI anchor signal (GPI). CSP1 andCSP2
were produced by expression in Escherichia coli, CSP3 and CSP4 by expression in P. pastoris.
CSP and Adjuvants Induce Antibody-Mediated Protection
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One) according to the manufacturer’s instructions. After several washes,
cells were cryopreserved.
Statistics. Themajority of the data and statistical analysis were created
using Prism software (GraphPad) and a Mann-Whitney test. Differences
were found to be significant when P was less than 0.05 or 0.01. Data are
represented as means  standard deviations (SD) or as geometrical
means, as indicated in the figure legends. Bar and pie charts of cytokine
production were created using FlowJo software (Tree Star), Pestle, and
SPICE (Mario Roederer, NIAID, NIH).
RESULTS
E. coli-derived CSP induces robust CD4 T cell cytokine re-
sponses. The goal of this blinded study was to compare the im-
munogenicities of four full-length CSPs (CSP1 to -4) in combina-
tion with different adjuvants. CSP1 andCSP2were produced in E.
coli, while CSP3 and CSP4 were expressed in the yeast P. pastoris.
The amino acid sequences of CSP2 and CSP3, derived from the
3D7 strain of the malaria parasite, share strong homology at the
amino- and carboxy-terminal regions but differ in their numbers
of NANP repeats (Fig. 1). CSP1 and CSP4 are derived from the
India strain IND637HDD1, contain all 37 NANP repeats, and
share strong amino acid sequence homology. The 3D7 strain has a
deletion in the N-terminal region (aa 91 to 97), whereas this re-
gion is intact in the India strain. We first selected poly(I·C)LC as
an adjuvant based on its potency for generating T cell and anti-
body responses shown in prior studies by our lab and others (34,
35). C57BL/6 mice were immunized twice, 3 weeks apart, with 2
g or 20 g of CSP with or without 50 g poly(I·C)LC. Four
weeks after the second immunization, CD4 T cell responses in
FIG 2 C57BL/6 mice (n 4) were immunized twice, 3 weeks apart, with either 2g or 20g of various CSPs and 50g poly(I·C)LC. Naive mice andmice that
received poly(I·C)LC alone or 20 g of each protein alone served as controls. Four weeks later, T cells in spleens were analyzed for cytokine production by flow
cytometry. Frequencies of CSP-specific IFN--, IL-2-, TNF--, or IL-10-producing CD4T cells are shown for protein-only and control mice (A) andmice that
received either 2g (B) or 20g (C) of CSP with poly(I·C)LC. Data are expressed as means SD and are representative of two independent experiments. *, P	
0.05. The color of the asterisk indicates the group to which the value is being compared.
FIG 3 C57BL/6 mice (n  4) were immunized as described in the legend of
Fig. 2. At the time of tissue harvest, sera were collected and analyzed for CSP-
specific IgG antibodies in protein-only and control mice (A) and mice that
received either 2g (B) or 20g (C) ofCSPwith poly(I·C)LC.Antibodieswere
measured against part of the repeat region ([NANP]6). Data points are
graphed as geometrical means of endpoint titers and are representative of two
independent experiments. *, P 	 0.05. The color of the asterisk indicates the
group to which the value is being compared.
Kastenmüller et al.
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the spleens were assessed bymultiparameter flow cytometry.Mice
immunizedwith poly(I·C)LC or any of the CSPswithout adjuvant
had no measurable CSP-specific CD4 T cell cytokine responses
(Fig. 2A). In contrast, 2 g of CSP1 and CSP2 administered with
poly(I·C)LC induced robust CD4T cell cytokine responses, pro-
ducing IFN-, IL-2, and TNF- (Fig. 2B). Such responses were
increased 2- to 3-fold by using 20 g of CSP with poly(I·C)LC
(Fig. 2C). Remarkably, both CSPs produced in yeast (CSP3 and
CSP4) failed to induce significant antigen-specific CD4 T cell
responses with poly(I·C)LC, even at the higher dose (20 g).
E. coli-derived CSP induces antibodies against the NANP re-
peat region. Since antibodies against CSP are critical for protec-
tion, we assessed responses against the NANP repeat region fol-
lowing immunization of all vaccine groups. Consistent with the
data in Fig. 2, CSP1 and CSP2 vaccines produced in E. coli elicited
significantly more potent antibody responses than did CSP3 and
CSP4 expressed in yeast (Fig. 3A toC).Higher antibody titers were
observed inmice that received the higher dose (20g) of CSP and
poly(I·C)LC. Taken together, the E. coli-derived proteins were
more potent for CSP-specific antibody andCD4T cell immunity
in this study with poly(I·C)LC or with CpG as an adjuvant (data
not shown). Therefore, CSP1 was selected for further testing.
Protection requires three immunizations with CSP and
poly(I·C)LC.Wenext sought to establish the optimal antigen dose
and number of immunizations required to induce protection
against a challenge. Because mice are not susceptible to P. falcip-
arum, we used a recombinant P. berghei parasite expressing the P.
falciparum CSP repeat region [Pb-CS(Pf)] (10) as a challenge for
our P. falciparum CSP-vaccinated mice. Mice were immunized
two or three times at 3-week intervals with 20 g of CSP1 and
poly(I·C)LC. Four weeks after the last immunization, mice were
challenged i.v. with 1.5  104 Pb-CS(Pf) parasites. Forty hours
later, livers of infected mice were harvested and parasite-derived
18S rRNA was measured by real-time qPCR (RT-qPCR). Mice
that received two immunizations with 20 g of CSP1 and
poly(I·C)LC showed a modest but significant (0.5 log) reduc-
tion (P	 0.01) of parasite-derived 18S rRNA levels compared to
naive mice or mice that received poly(I·C)LC or CSP1 alone (Fig.
4A). Moreover, three immunizations with 20 g CSP1 and
poly(I·C)LC resulted in an 2- to 4-log reduction in 18S rRNA
(Fig. 4A) compared to levels in mice immunized with protein
alone, poly(I·C)LC alone, or CSP1 protein and poly(I·C)LC (two
immunizations). A separate series of experiments sought to deter-
mine whether the dose of CSP1 influenced protection. We com-
pared three immunizations with 2 or 20 g of CSP1 and
poly(I·C)LC. As shown in Fig. 4B, the higher dose of CSP1 pro-
vided a significant (P 0.005) (2-log) reduction in parasite load
in the livers of mice compared to those with the lower dose of
CSP1. Overall, these data show that three immunizations with the
higher dose (20g) of CSP1 and poly(I·C)LC provided significant
reduction of parasite load against a high-dose i.v. challenge with
sporozoites.
Antibody against CSP correlates with protection. In the next
series of experiments, we sought to determine the immunological
correlates of protection following immunization with CSP1 and
poly(I·C)LC. Prior studies in mice and humans showed that anti-
bodies and CD4 T cells play a role in protection (20, 22, 44–48).
In Fig. 3, we show that two immunizationswith 2 or 20g of CSP1
induced potent antibody responses against the NANP repeat re-
gion. To extend this analysis, we assessed CSP-specific antibody
FIG 4 C57BL/6mice (n 6) were immunized two or three times, 3 weeks apart,
with2or20gofCSP1and50gpoly(I·C)LC.Naivemice andmice that received
poly(I·C)LC alone or 20 g of CSP1 alone served as controls. Four weeks later,
mice were challenged with 1.5 104 Pb-CS(Pf) sporozoites. Parasite burden was
determined 40hpostchallenge by counting the copies of 18S rRNA in the livers by
RT-PCR. Shown are comparisons of levels of protective immunity in mice that
received either twoor three immunizations of 20gCSP1 andpoly(I·C)LC (A)or
three immunizations with 2 g or 20 g CSP1 and poly(I·C)LC (B). Data points
are graphed as geometrical means and are representative of two independent ex-
periments *,P	0.05; **,P	0.01.Thecolorof theasterisk (A)or the lengthof the
bar (B) indicates the group to which the value is being compared.
FIG 5 (A) C57BL/6 mice (n 4 to 6) were immunized two or three times, 3
weeks apart, with 2 or 20 g of CSP1 and 50 g poly(I·C)LC. Naive mice and
mice that received poly(I·C)LC alone or 20 g of CSP1 alone served as con-
trols. Two weeks later, sera were collected and CSP-specific IgG antibodies
were determined. Data points are graphed as means  SD. *, P 	 0.05. The
values for all control groups are significantly lower than those for vaccine
groups. (B) Serum from mice immunized three times with CSP1 and
poly(I·C)LC or serum from naive mice was transferred into naive mice at the
time of challenge with 1.5  104 Pb-CS(Pf) sporozoites. Vaccinated mice
(CSP1 and poly(I·C)LC) served as a positive control. Forty hours postchal-
lenge, parasite burden was determined by counting the copies of 18S rRNA in
the livers by RT-PCR. Black bars show the geometrical means. **, P 	 0.01.
Results are representative of at least two independent experiments.
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titers at both doses of CSP after two or three immunizations. As
shown in Fig. 5A, the greatest antibody responsewas detectedwith
the higher dose of CSP1 given three times, consistent with im-
proved protection in this group (Fig. 4). To substantiate a direct
role of antibodies in mediating protection, pooled serum from
mice immunized three times with 20 g CSP1 and poly(I·C)LC
was transferred into naive recipients, and then themice were chal-
lenged. As a negative control, serum from naive mice was trans-
ferred to naive mice. As a positive control, mice immunized three
times with 20 g of CSP1 and poly(I·C)LC were challenged at the
same time. Naive mice that received serum from CSP1- and
poly(I·C)LC-vaccinated animals showed an 1-log reduction in
parasite burden compared to mice that received control serum or
naivemice (Fig. 5B).However, this protectionwas not as robust as
that seen in animals immunized with CSP1 and poly(I·C)LC. This
could be due to dilution of transferred antibodies in the blood of
recipient animals or to a contribution of vaccine-elicited CD4 T
cells absent in passively transferred animals. Nevertheless, these
data show that humoral immunity is sufficient to confer some
protection against this high-dose challenge.
Poly(I·C)LC induces higher CD4 Th1 cell immunity than
GLA-SE. The RTS,S vaccine has been formulated with the TLR4
ligand MPL and QS-21 in either a liposomal solution (AS01) or
oil-in-water emulsion (AS02). Thus, to compare poly(I·C)LC
(which signals through TLR3 and MDA-5) to an adjuvant with
some commonality toAS02, we chooseGLA-SE. This formulation
consists of a synthetic form of the TLR4 agonist lipid A, which has
been shown to provide adjuvant activity that is similar to, if not
better than, that of MPL-SE (49).
Mice were immunized three times with 2 g or 20 g of CSP1
formulated with either poly(I·C)LC or GLA-SE, and the CD4 T
cell responses were analyzed in the blood, spleen, and liver 7 to 14
days after the third vaccination. At this peak time point, the fre-
quencies of IFN--producing CD4 T cells in the blood (Fig. 6A)
were similar when we compared the 2-g and 20-g doses of
CSP1 protein using either poly(I·C)LC or GLA-SE as an adjuvant.
However, CD4 IFN- responses were significantly higher when
poly(I·C)LC was used than when GLA-SE was used for both doses
of CSP1 (Fig. 6A). Moreover, in spleen (Fig. 6B) and liver (Fig.
6C), CD4 T cell responses were also significantly higher using
poly(I·C)LC than using GLA-SE.Mice immunized with either ad-
juvant alone or CSP1 alone showed no detectable CD4 T cell
responses (data not shown). Lastly, we did not detect any CD8 T
cell responses (data not shown), consistent with the absence of aP.
falciparum CSP-specific CD8 T cell epitope in C57BL/6 mice.
To extend this analysis, we assessed the quality of the CD4 T
cell cytokine response based on the relative proportions of cells
producing IL-2, IFN-, and TNF-, either alone or simultane-
ously. The quality of the CD4 T cell response may be an impor-
tantmetric because of evidence thatmultifunctional CD4T cells
correlate with protection (20, 23, 50). As shown in Fig. 6D,50%
of the total cytokine-producing responses were multifunctional,
producing IL-2, TNF-, and IFN-, with another25% making
IFN- and TNF- without IL-2. Thus, both adjuvants elicit the
induction of CD4 T cells that secrete two critical effector cyto-
kines that may mediate parasite killing (51–53).
Poly(I·C)LC and GLA-SE confer comparable levels of protec-
tion correlating with antibody titers. We next compared anti-
body responses induced with 2 or 20 g of CSP1 and GLA-SE to
poly(I·C)LC following three immunizations. In contrast to the
FIG 6 C57BL/6 mice (n 6 to 18) were immunized three times, 3 weeks apart, with the indicated doses of CSP1 with either 50 g poly(I·C)LC or 5g GLA-SE
as the adjuvant. Mice that received poly(I·C)LC, GLA-SE, or CSP1 alone, mice that received CSP1 and SE, or naive mice served as controls (not shown). CD4
T cells in blood, spleen, and liver were analyzed for cytokine production by flow cytometry. (A) Frequencies of CSP-specific IFN--producing CD4 T cells in
the blood 7 days after the third immunization; (B, C) frequencies of CSP-specific IFN--, IL-2-, TNF--, or IL-10-producing CD4 T cells in the spleen (B) and
liver (C) 2 weeks after three immunizations; (D) relative proportions of each individual combination of IFN--, IL-2-, or TNF--producing cells in the spleen
and liver 2 weeks after three immunizations. ND, not determined (because the frequency was too low). The black circle represents the percentage of CD4T cells
that make IFN-. Bars show the means 
 SD. *, P 	 0.05; **, P 	 0.01. All control groups had values below the limit of detection. The color of the asterisk
indicates the group to which the value is being compared. Results are representative of two independent experiments.
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magnitudes of CD4T cell cytokine responses, which were signif-
icantly different, the total titers of IgG against the NANP re-
peats measured with the two adjuvants were not significantly
different (Fig. 7A, upper left). Of note, the lower dose (2 g) of
CSP1 consistently induced 2- to 5-fold-lower total antibody
titers than the higher dose (20 g) for both adjuvants. Similar
results were seen after analyzing IgG1 and IgG2a antibody titers
(Fig. 7A). In terms of protection, there was a 2- to 3-log reduc-
tion of 18S rRNA after challenge with Pb-CS(Pf) in mice im-
munized with 20 g of CSP1 with poly(I·C)LC compared to
that in naive mice, consistent with the results of previous ex-
periments (Fig. 4). Immunization with 20 g of CSP1 and
GLA-SE resulted in similar levels of protection (Fig. 7B). Thus,
in a setting of equivalent antibody titers, there was no signifi-
cant difference in protection using poly(I·C)LC or GLA-SE as
an adjuvant.
To determine whether humoral or cellular immune responses
correlated with protection, prechallenge antibody titers (Fig. 7C)
andCD4T cell cytokine responses (Fig. 7D)were plotted against
the level of protection achieved upon consecutive challenge. There
was a highly significant correlation betweenCSP-specific antibody
titers and the level of 18S rRNA measured in livers after parasite
challenge (Pearson r0.7) (Fig. 7C). In contrast, there was no
correlation between the frequency of IFN--producing CD4 T
FIG 7 C57BL/6 mice (n  6) were immunized three times, 3 weeks apart, with the indicated doses of CSP1 together with either 50 g poly(I·C)LC or 5 g
GLA-SE.Mice that received poly(I·C)LC,GLA-SE, or CSP1 (20g) alone or naivemice served as controls. (A) Twoweeks after the third immunization, serawere
collected and CSP-specific IgG, IgG1, and IgG2a antibodies were measured. Bars are graphed as means 
 SD. All control groups showed significantly lower
antibody titers than the vaccine groups. (B) Four weeks after the third immunization, mice were challenged with 1.5 104 Pb-CS(Pf) sporozoites. Forty hours
postchallenge, parasite burden was determined by counting 18S rRNA copies in the livers by RT-PCR. Black bars show the geometrical means. The matrix (B)
represents significances among various immunization groups. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001. (C) Correlation between antibody titers and parasite
burden in the liver. (D) Correlation between frequency of IFN--producing CD4 T cells in the blood (day 7) and parasite burden in the liver. (C and D) As
indicated, Pearson’s r was calculated. Results are representative of at least two independent experiments.
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cells in the blood and the level protection after parasite challenge
(Pearson r  0.02) (Fig. 7D). Finally, to confirm that our vac-
cine-elicited CSP-specific antibodies had binding activity against
the intact parasite, we used an IFA assay to visualize direct anti-
body binding to sporozoites (Table 1). Consistent with the CSP-
specific antibody titers, poly(I·C)LC and GLA-SE induced strong
and comparable IFA titers when they were administered with 20
g of CSP1 protein. Taken together, these data show that
poly(I·C)LC and GLA-SE differ in their capacities to induce
CD4/Th1 immune responses after immunization with CSP;
however, they induce comparable antibody responses that corre-
late best with protection.
While reduction in parasite load in the liver following a high-
dose i.v. challenge may have important clinical consequences by
reducing the prepatent period and time to infection (20, 54, 55),
the most important and clearest clinical outcome is sterilizing
immunity. Thus, mice vaccinated with CSP1 and poly(I·C)LC
were i.v. challenged with a low dose of 1 103 Pb-CS(Pf) sporo-
zoites andmonitored daily by blood smear to establish the onset of
infection. As shown in Fig. 8, all naive mice and mice immunized
with poly(I·C)LC alone developed parasitemia within 5 days. In
contrast, 5 out of 10mice immunized with CSP1 and poly(I·C)LC
did not develop parasitemia during the 15 days of follow-up. Also,
the prepatent period was significantly delayed (P	 0.05) in mice
that received CSP1 and poly(I·C)LC (5.8 days) compared to mice
that received poly(I·C)LC alone or naive animals (4.6 days and 4.8
days, respectively) (Fig. 8A; Table 2). Analysis of prechallenge sera
from mice vaccinated with CSP1 and poly(I·C)LC revealed that
protected mice from this group displayed significantly higher an-
tibody titers than the nonprotected mice from this same vaccine
group (Fig. 8B). These data are consistentwith human trials show-
ing that a very high level of antibody is required for sterilizing
immunity (20, 56).
CSP and poly(I·C)LC induce humoral and cellular responses
in NHPs. Based on the results from the mouse studies, we deter-
mined whether CSP1 and poly(I·C)LC could induce potent anti-
body andCD4T cell responses inNHPs. NHPs are amore useful
animal model than mice for testing vaccine adjuvants because of
greater similarities to humans, with respect to innate immune
pathways and TLR expression. Rhesus macaques received either
two or three immunizations of 100gCSP1 and poly(I·C)LC, and
CD4 T cell and antibody responses were assessed at different
time points after immunization. For CD4 T cell cytokine re-
sponses, a batch analysis was done on frozen PBMCs from various
time points. As shown in Fig. S1 in the supplemental material, as
with the mouse data in Fig. 2, the frequency of CSP-specific cyto-
kine-producing CD4 T cells is increased in NHPs that received
three immunizations rather than only two immunizations (see
Fig. S1A and B in the supplemental material), with a substantial
portion ofmultifunctional cells secreting IFN-, IL-2, and TNF-
or IFN- and TNF- (Fig. S1C and D). There were also robust
CSP antibody titers that were maximal after two immunizations
with CSP1 and poly(I·C)LC. Waning antibody titers could be
boosted with a third immunization but did not exceed the levels
that were reached after two immunizations (Fig. S1E and F).
Moreover, in the IFA assay, sera from animals that received three
immunizations contained antibodies with a stronger binding ca-
TABLE 1 Antibodies in sera from mice that were immunized with a high dose of CSP1 and adjuvant showed a strong binding capacity to
sporozoites in vitro
Vaccine
Binding of serum antibodies to sporozoites as determined by fluorescence intensity at an antibody dilution ofa:
1:300 1:900 1:2,700 1:8,100 1:24,300 1:72,900
Poly(I·C)LC      
GLA-SE      
CSP  /    
2 g CSP GLA-SE      
2 g CSP poly(I·C)LC   / /  
20 g CSP GLA-SE      /
20 g CSP poly(I·C)LC      /
a Serum samples that were collected 2 weeks after the third immunization (as described in the legend of Fig. 6) were pooled by group. The serum pools at different dilutions were
incubated on slides coated with fixed sporozoites. The slides were washed and incubated with a secondary fluorescently labeled antibody. Finally, slides were analyzed under a
microscope., very good binding;, good binding;, weak binding;, no binding. Results are representative of two independent experiments.
FIG 8 C57BL/6mice (n 10 per group)were immunized three times, 3 weeks
apart, with 20 g of CSP1 together with 50 g poly(I·C)LC as the adjuvant.
Mice that received poly(I·C)LC or naive mice served as controls. (A) Five
weeks later, mice were challenged i.v. with 1  103 Pb-CS(Pf) sporozoites.
Starting on day 4, daily blood smears were taken and analyzed under a micro-
scope. Kaplan-Meier plots show the time to detection of parasites in the blood
for each vaccine group after the challenge. (B) Sera collected 3 weeks before
challenge were analyzed for CSP-specific IgG antibodies. Endpoint titers are
grouped by whether mice went on to be protected from challenge. *, P	 0.05.
Results are representative of two independent experiments.
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pacity than those from animals that received two immunizations
(see Table S1 in the supplemental material). Therefore, we con-
clude that the CSP1 protein and poly(I·C)LC are strongly immu-
nogenic in NHPs.
DISCUSSION
Currently, the RTS,S vaccine administered with AS01 is the most
advanced malaria vaccine, providing 30 to 50% protection in
humans (2, 3). The recent results of the pivotal phase III clinical
efficacy trial were amajor breakthrough in establishing that a pro-
tein/particle-based vaccine with a well-formulated adjuvant sys-
tem could achieve some protective efficacy against a parasite in-
fection and confirms this approach as a first step toward
developing a successful malaria vaccine. In the study presented
here, we compared various full-length CS proteins for their ability
to induce strong immunity and protection. Such proteins were
provided by four partners, in partnership with MVI, to enable
direct comparison anddown-selection of one ormore proteins for
further development, thereby providing a potentially simpler for-
mulation than RTS,S/AS01 with comparable or improved effi-
cacy. The data presented here using poly(I·C)LC as an adjuvant
show a striking difference between the immunogenicities elicited
by E. coli-derived CSP and yeast-derived CSP. The relatively low
responses to the yeast-derived protein were surprising, since
RTS,S (as well as other successful protein-based vaccines) is pro-
duced in yeast (57) and one of the yeast-derived proteins used in
this study when given with Montanide did elicit potent antibody
titers in mice (data not shown), showing that at least for antibody
responses, the yeast-derived protein was immunogenic. We spec-
ulate that differences in the amino acid sequences or mannosyla-
tion sites of CSPs expressed in yeast and E. coli may have ac-
counted for the limited immunogenicity. Indeed, one of the
yeast-derived proteins induced higher antibody and CD4 T cell
responses when the same amino acid sequence was expressed in E.
coli (data not shown). However, modifications in the mannosyla-
tion sites did not significantly alter the immunogenicity of yeast-
expressed CSP (data not shown). Therefore, the mechanistic basis
for the differences in immunogenicity of yeast- and E. coli-ex-
pressed CSPs used in this experiment is not entirely clear. In view
of these results, CSP1 was used with the two adjuvants,
poly(I·C)LC and GLA-SE, for the remainder of the studies.
Both poly(I·C)LC and GLA-SE elicited strong and comparable
levels of CSP-specific IgG antibody titers, which conferred similar
degrees of protection against high-dose sporozoite challenge.
However, poly(I·C)LC induced a substantially higher frequency of
CSP-specificCD4T cell cytokine responses thanGLA-SE.More-
over, such responses were comprised of a large percentage ofmul-
tifunctional cells secreting IFN-, IL-2, and TNF-, which have
been proposed to contribute to antimalarial protection after
RTS,S/AS01 vaccination (20, 23). Of note, while vaccination with
CSP (P. vivax) and GLA-SE in mice has been shown to induce a
robust CD4 T cell effector response (58), the same vaccine in-
duced monofunctional (IL-2 only) CD4 T cell responses in
NHPs (49). In contrast, we show that CSP and poly(I·C)LC in-
duced robust multifunctional Th1 CD4 T cell responses in both
mice and NHPs. These data highlight potential differences in the
magnitudes and quality of CD4 T cell responses induced inmice
and NHPs and are consistent with the results of other studies
showing poly(I·C) or poly(I·C)LC to be an especially potent adju-
vant in NHPs for such responses (34, 59). Finally, it is notable that
despite the dramatic differences in the CD4/Th1 responses be-
tween poly(I·C)LC and GLA-SE in mice, the antibody titers were
similar. These data highlight the possibility that adjuvants can
differentially mediate effects on antibody and Th1 immunity,
which is currently being investigated.
In terms of correlates of protection, both antibody andCD4T
cells have been described to occur in mice or humans with CSP
vaccines.Here, we show that the antibody titers using poly(I·C)LC
orGLA-SE strongly correlatewith protection (Fig. 7C).Moreover,
serum transfer from CSP-immunized animals reduced the para-
site burden after high-dose i.v. challenge. Thus, antibodies are
necessary and sufficient in thismodel.Of note, protectionwas best
with the higher dose of CSP (20 g), which induced an 1-log
increase in antibody titer compared to that induced by the lower
dose of protein (2g). It is notable that, in humans, 25g or 50g
of RTS,S induced antibody titers better than and comparable to
those induced by 10 g, suggesting some dose effect similar to
what we observed in this study (60). This suggests that there may
be a threshold for the amount of CSP-specific antibody required
to provide or increase protection. Indeed, when we analyzed an-
tibody titers from protected and nonprotected animals (Fig. 7C
and 8B), there was a threshold for the amount of antibody re-
quired to mediate protection after low- or high-dose challenge.
This is consistent with data from humans in which anti-CSP an-
tibody titers needed to be above 40 EU/ml (56) to induce protec-
tion. In addition, we show that nonprotected mice had a signifi-
cantly delayed prepatent period compared to the control animals
(Table 2). Accordingly, studies using RTS,S and different adju-
vants in humans also show that the prepatent period can be de-
layed. At present, it still is not clear whether this delay might play
a role in improving the clinical outcome of amalaria infection (20,
54, 55).
Regarding the role of cellular immunity in mediating protec-
tion, previous studies have shown that CD4 T cells specific for P.
yoeliiCSP eliminate infected hepatocytes in vitro and, when adop-
tively transferred, mediate protection in vivo (61, 62). The protec-
tive role of CD4 effector cells against malaria was further sub-
stantiated in other murine and human malaria models (22, 63,
64). In data not shown, antibody depletion of CD4 T cells in
mice immunizedwith CSP1 and poly(I·C)LC at the time of sporo-
zoite challenge resulted in only modestly reduced protection.
Hence, in our model, the data support a far more critical role for
CSP antibodies in mediating protection than for CD4 effector T
TABLE 2 Vaccination with CSP1 and poly(I·C)LC prevents 50% of












20 g CSP poly(I·C)LC 5/10 5.8 50
Poly(I·C)LC 10/10 4.6 0
None (naive mice) 10/10 4.8 0
a C57BL/6 mice (n 10/group) were immunized three times, 3 weeks apart, with 20 g
CSP1 together with 50 g poly(I·C)LC as the adjuvant. Mice that received poly(I·C)LC
only or naive mice served as controls. Five weeks after the last immunization, mice were
challenged i.v. with 1 103 Pb-CS(Pf) sporozoites. Starting at day 4, daily blood smears
were taken and observed under a microscope to look for the onset of parasitemia.
Results are representative of two independent experiments.
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cells. Nevertheless, human studies using the AS02 or AS01 adju-
vant showing that improved CD4 T cell responses were associ-
ated with improved protection after challenge with P. falciparum
(20, 22) provide evidence for the importance of these T cells.
Therefore, the ability of poly(I·C)LC to elicit such potent CD4 T
cells in blood, liver, and spleen may be of importance in humans
through a variety of mechanisms. Indeed, IFN- has been shown
to inhibit the development of liver-stagemalaria in various animal
models (52, 65). Thatwould provide a potential advantageous role
for poly(I·C)LC, based on the high frequency of those cells de-
tected in the livers of immunized mice.
There is also strong evidence for cytotoxic CD8 T cells in
mediating protective immunity against liver-stagemalaria (18, 46,
66, 67). As our study used a strain of mice in which there was no
major histocompatibility complex (MHC) class I recognition ofP.
falciparum CSP peptides, we did not detect any CD8 T cell re-
sponses. However, we and others have previously shown that type
I IFN is essential for mediating cross-priming of protein in mice
(68, 69), highlighting the potential advantage of poly(I·C)LC over
other adjuvants (25). Nevertheless, while adjuvants that induce
type I IFN should be preferred to induce CD8 T cell responses
upon protein vaccination, virus-based vaccines seem preferable if
robust CD8 T cell immunity is required. Improving how the
protein is formulated and targeting it to specific dendritic cell
subsets may ultimately improve the capacity of such vaccines to
consistently and efficiently induce CD8 T cells.
In conclusion, we show that a full-length P. falciparumCS pro-
tein when combined with poly(I·C)LC or GLA-SE induces potent
immunity and protection in mice. Moreover, poly(I·C)LC is an
effective adjuvant for eliciting such responses in NHPs, providing
a predictive model for what might occur in humans (20, 21, 70,
71). It is possible that the increased breadth of CSP responses with
a full-length CSP (compared to the CSP responses with truncated
RTS,S) and/or the enhanced CD4 Th1 immunity that would
potentially be elicited by poly(I·C)LC would enhance protection
and/or durability. Whether a full-length protein vaccine with an
adjuvant would substantially improve the outcome over the cur-
rent platforms of RTS,S/AS01 and RTS,S/AS02, which have the
advantages of being particles with well-formulated adjuvants and
of being safe and scalable, remains a question for further develop-
ment. Our study shows that a protein platform can provide effec-
tive protection againstmalaria. The key question for future studies
is whether this protection will also provide a prolonged durability
compared to that of the RTS,S vaccine.
ACKNOWLEDGMENTS
We thank P. A. Darrah for critically reading the manuscript and D.
Berry and C. J. Redmond for technical support. Also we thank S. Reed
for providing GLA-SE and the Malaria Serology Laboratory at WRAIR
for their help with the serum samples. The proteins were provided
through agreements between PATH Malaria Vaccine Initiative (MVI)
and its partners.
We thank MVI for funding and facilitating this comparative study
by identifying and accessing the proteins and ensuring agreement of all
partners on the final study design. We thank Gennova Biopharmaceu-
ticals and WRAIR for providing the proteins CSP1 and CSP2, respec-
tively.
REFERENCES
1. WHO. 2011. World malaria report 2011. World Health Organization,
Geneva, Switzerland. http://www.who.int/malaria/world_malaria_report
_2011/en/.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP,
Conzelmann C, Methogo BGNO, Doucka Y, Flamen A, Mordmüller B,
Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ,
Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P,
Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad
AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM,
Mwangoka G, Tanner M, Tinto H, D’Alessandro U, Sorgho H, Valea I,
Tahita MC, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé RT,
Ouédraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K,
Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker
L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B,
Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R,
Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon
P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K,
Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I,
Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase
S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M,
Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng
HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L,
Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A,
Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M,
Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-
Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A,
Savarese B, Schellenberg D, Sillman M, Vansadia P, RTS,S Clinical
Trials Partnership. 2011. First results of phase 3 trial of RTS,S/AS01
malaria vaccine in African children. N. Engl. J. Med. 365:1863–1875.
3. The RTS,S Clinical Trials Partnership. 2012. A phase 3 trial of RTS,S/
AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284–2295.
4. Shi YP, Udhayakumar V, Alpers MP, Povoa MM, Oloo AJ, Ruebush
TK, II, Lal AA. 1993. Natural antibody responses against the non-repeat-
sequence-based B-cell epitopes of the Plasmodium falciparum circum-
sporozoite protein. Infect. Immun. 61:2425–2433.
5. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso
P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G. 2009. The
N-terminal domain of Plasmodium falciparum circumsporozoite protein
represents a target of protective immunity. Vaccine 27:328–335.
6. Rathore D, Nagarkatti R, Jani D, Chattopadhyay R, de la Vega P,
Kumar S, McCutchan TF. 2005. An immunologically cryptic epitope of
Plasmodium falciparum circumsporozoite protein facilitates liver cell rec-
ognition and induces protective antibodies that block liver cell invasion. J.
Biol. Chem. 280:20524–20529.
7. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. 2005. The Plasmodium
circumsporozoite protein is proteolytically processed during cell invasion.
J. Exp. Med. 201:27–33.
8. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA,
Corradin G, Persson C, Tewari R, Sinnis P. 2011. The malaria circum-
sporozoite protein has two functional domains, each with distinct roles as
sporozoites journey from mosquito to mammalian host. J. Exp. Med.
208:341–356.
9. Zavala F, Tam JP, Barr PJ, Romero PJ, Ley V, Nussenzweig RS,
Nussenzweig V. 1987. Synthetic peptide vaccine confers protection
against murine malaria. J. Exp. Med. 166:1591–1596.
10. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin
E. 2002. Cutting edge: a new tool to evaluate human pre-erythrocytic
malaria vaccines: rodent parasites bearing a hybrid Plasmodium falcipa-
rum circumsporozoite protein. J. Immunol. 169:6681–6685.
11. Nussenzweig V, Nussenzweig RS. 1989. Rationale for the development of
an engineered sporozoite malaria vaccine. Adv. Immunol. 45:283–334.
12. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que
JU, Cryz SJ, Sadoff JC. 1992. Safety, immunogenicity, and efficacy of a
Plasmodium falciparum vaccine comprising a circumsporozoite protein
repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.
Infect. Immun. 60:1834–1839.
13. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M,
Silverman C, Alving CR. 1992. Liposomal malaria vaccine in humans: a
safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U. S. A. 89:358–
362.
14. Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M,
Gordon D, Church P, Gross M, Silverman C. 1994. Safety, immunoge-
nicity, and efficacy of a malaria sporozoite vaccine administered with
monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane
as adjuvant. Am. J. Trop. Med. Hyg. 51:603–612.
15. Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB,
Kastenmüller et al.
798 iai.asm.org Infection and Immunity
Strickland GT, Gordon DM, Ballou WR, Bales JD, Wirtz RA, Wittes J,
Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC. 1996.
Plasmodium falciparum circumsporozoite vaccine immunogenicity and
efficacy trial with natural challenge quantitation in an area of endemic
human malaria of Kenya. Vaccine 14:817–827.
16. Sherwood JA, Oster CN, Adoyo-Adoyo M, Beier JC, Gachihi GS,
Nyakundi PM, Ballou WR, Brandling-Bennett AD, Schwartz IK, Were
JB. 1991. Safety and immunogenicity of a Plasmodium falciparum sporo-
zoite vaccine: boosting of antibody response in a population with prior
natural exposure to malaria. Trans. R. Soc. Trop. Med. Hyg. 85:336–340.
17. Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego
JW, Krinchai K, Su-archawaratana, Wongsrichanalai PC, Ballou WR.
1994. Safety, immunogenicity and limited efficacy study of a recombinant
Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vac-
cine 12:102–108.
18. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R,
Nussenzweig V. 1987. Gamma interferon, CD8 T cells and antibodies
required for immunity to malaria sporozoites. Nature 330:664–666.
19. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. 1988.
CD8 T cells (cytotoxic/suppressors) are required for protection in mice
immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U. S. A. 85:
573–576.
20. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych
U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L,
Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois Lievens M-CM,
Cohen J, Ballou WR, Heppner DG, RTS,S Vaccine Evaluation Group.
2009. Randomized, double-blind, phase 2a trial of falciparum malaria
vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety,
efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337–
346.
21. Mettens P, Dubois PM, Demoitié Bayat M-AB, Donner Bourguignon
M-NP, Stewart VA, Heppner DG, Garçon N, Cohen J. 2008. Improved
T cell responses to Plasmodium falciparum circumsporozoite protein in
mice and monkeys induced by a novel formulation of RTS,S vaccine an-
tigen. Vaccine 26:1072–1082.
22. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G,
Kester KE, Heppner DG, Krzych U. 2003. Protective immunity induced
with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circum-
sporozoite protein-specific CD4 and CD8 T cells producing IFN-
gamma. J. Immunol. 171:6961–6967.
23. Lumsden JM, Schwenk RJ, Rein LE, Moris P, Janssens M, Ofori-
Anyinam O, Cohen J, Kester KE, Heppner DG, Krzych U. 2011.
Protective immunity inducedwith theRTS,S/AS vaccine is associatedwith
IL-2 and TNF- producing effector and central memory CD4 T cells.
PLoS One 6:e20775. doi:10.1371/journal.pone.0020775.
24. Regules JA, Cummings JF, Ockenhouse CF. 2011. The RTS,S vaccine
candidate for malaria. Expert Rev. Vaccines 10:589–599.
25. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C,
Salazar AM, Colonna M, Steinman RM. 2009. Dendritic cells require a
systemic type I interferon response to mature and induce CD4 Th1
immunity with poly IC as adjuvant. J. Exp. Med. 206:1589–1602.
26. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough
DF. 2001. Type I interferons potently enhance humoral immunity and can
promote isotype switching by stimulating dendritic cells in vivo. Immu-
nity 14:461–470.
27. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke
U, Tough DF. 2006. Cutting edge: enhancement of antibody responses
through direct stimulation of B and T cells by type I IFN. J. Immunol.
176:2074–2078.
28. Ma Y, Ross AC. 2009. Toll-like receptor 3 ligand and retinoic acid en-
hance germinal center formation and increase the tetanus toxoid vaccine
response. Clin. Vaccine Immunol. 16:1476–1484.
29. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura Taka-
hashi S-IH, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2005.
Synthetic double-stranded RNA poly(I:C) combined with mucosal vac-
cine protects against influenza virus infection. J. Virol. 79:2910–2919.
30. Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ,
Restifo NP, Smyth MJ, Darcy PK, Kershaw MH. 2011. Adoptive immu-
notherapy combined with intratumoral TLR agonist delivery eradicates
established melanoma in mice. Cancer Immunol. Immunother. 60:671–
683.
31. Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F,
Sarobe P. 2008. Combined immunization with adjuvant molecules
poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic
and therapeutic antitumor effects. Cancer Immunol. Immunother. 57:
19–29.
32. Cui Z, Qiu F. 2006. Synthetic double-stranded RNA poly(I:C) as a potent
peptide vaccine adjuvant: therapeutic activity against human cervical can-
cer in a rodent model. Cancer Immunol. Immunother. 55:1267–1279.
33. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ,
Vasilakos JP, Noelle RJ, Kedl RM. 2004. Combined TLR and CD40
triggering induces potent CD8 T cell expansion with variable depen-
dence on type I IFN. J. Exp. Med. 199:775–784.
34. Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M,
Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban
M, Park CG, Trumpfheller C, Keler T, Pantaleo G, Steinman RM, Seder
R. 2011. Immunization with HIV Gag targeted to dendritic cells followed
by recombinant New York vaccinia virus induces robust T-cell immunity
in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 108:7131–7136.
35. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K,
Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J,
Schulte R, Gissmann L, Müller M, Sacher A, Racz P, Steinman RM,
Uguccioni M, Ignatius R. 2009. Synthetic double-stranded RNAs are
adjuvants for the induction of T helper 1 and humoral immune responses
to human papillomavirus in rhesus macaques. PLoS Pathog. 5:e1000373.
doi:10.1371/journal.ppat.1000373.
36. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta
GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS. 2010.
Physicochemical characterization and biological activity of synthetic
TLR4 agonist formulations. Colloids Surf. B Biointerfaces 75:123–132.
37. Windish HP, Duthie MS, Ireton G, Lucas E, Laurance JD, Bailor RH,
Coler RN, Reed SG. 2011. Protection of mice from Mycobacterium tu-
berculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candi-
date. Vaccine 29:7842–7848.
38. Gomes R, Teixeira C, Oliveira F, Lawyer PG, Elnaiem DE, Meneses C,
Goto Y, Bhatia A, Howard RF, Reed SG, Valenzuela JG, Kamhawi S.
2012. KSAC, a defined Leishmania antigen, plus adjuvant protects against
the virulence of L. major transmitted by its natural vector Phlebotomus
duboscqi. PLoS Negl. Trop. Dis. 6:e1610. doi:10.1371/journal.pntd
.0001610.
39. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS,
Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg
CH, Van Hoeven N, Reed SG. 2010. A synthetic adjuvant to enhance and
expand immune responses to influenza vaccines. PLoSOne 5:e13677. doi:
10.1371/journal.pone.0013677.
40. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler
RN, Vedvick TS, Reed SG. 2009. Optimized subunit vaccine protects
against experimental leishmaniasis. Vaccine 27:7036–7045.
41. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M,
Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG. 2010.
A defined tuberculosis vaccine candidate boosts BCG and protects against
multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med.
2:53ra74. doi:10.1126/scitranslmed.3001094.
42. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D,
Koup RA, Roederer M. 2006. Amine reactive dyes: an effective tool to
discriminate live and dead cells in polychromatic flow cytometry. J. Im-
munol. Methods 313:199–208.
43. Bruña-Romero O, Hafalla JC, González-Aseguinolaza G, Sano G, Tsuji
M, Zavala F. 2001. Detection of malaria liver-stages in mice infected
through the bite of a single Anopheles mosquito using a highly sensitive
real-time PCR. Int. J. Parasitol. 31:1499–1502.
44. Tsuji M, Romero P, Nussenzweig RS, Zavala F. 1990. CD4 cytolytic T
cell clone confers protection against murine malaria. J. Exp. Med. 172:
1353–1357.
45. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. 1980. Mon-
ovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface
antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151:
1504–1513.
46. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, Mary-
anski JL, Nussenzweig RS, Zavala F. 1991. CD8 cytolytic T cell clones
derived against the Plasmodium yoelii circumsporozoite protein protect
against malaria. Int. Immunol. 3:579–585.
47. Rénia L, Grillot D, Marussig M, Corradin G, Miltgen F, Lambert PH,
Mazier D, Del Giudice G. 1993. Effector functions of circumsporozoite
peptide-primed CD4 T cell clones against Plasmodium yoelii liver
stages. J. Immunol. 150:1471–1478.
CSP and Adjuvants Induce Antibody-Mediated Protection
March 2013 Volume 81 Number 3 iai.asm.org 799
 
 
48. Reece WHH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T,
Plebanski M, Akinwunmi P, Everaere S, Watkins KR, Voss G, Torn-
ieporth N, Alloueche A, Greenwood BM, Kester KE, Mcadam KPWJ,
Cohen J, Hill AVS. 2004. A CD4() T-cell immune response to a con-
served epitope in the circumsporozoite protein correlates with protection
from natural Plasmodium falciparum infection and disease. Nat. Med.
10:406–410.
49. Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K,
Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick
TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse
CF, Howard RF, Yadava A. 2011. Evaluation of the safety and immuno-
genicity in rhesus monkeys of a recombinant malaria vaccine for Plasmo-
dium vivax with a synthetic Toll-like receptor 4 agonist formulated in an
emulsion. Infect. Immun. 79:3492–3500.
50. Moorthy VS, Ballou WR. 2009. Immunological mechanisms underlying
protection mediated by RTS,S: a review of the available data. Malar. J.
8:312.
51. Mendis KN, Naotunne TD, Karunaweera ND, Del Giudice G, Grau GE,
Carter R. 1990. Anti-parasite effects of cytokines in malaria. Immunol.
Lett. 25:217–220.
52. Vigario AM, Belnoue E, Cumano A, Marussig M, Miltgen F, Landau I,
Mazier D, Gresser I, Renia L. 2001. Inhibition of Plasmodium yoelii
blood-stagemalaria by interferon alpha through the inhibition of the pro-
duction of its target cell, the reticulocyte. Blood 97:3966–3971.
53. Depinay N, Franetich JF, Gruner AC, Mauduit M, Chavatte JM, Luty
AJ, van Gemert GJ, Sauerwein RW, Siksik JM, Hannoun L, Mazier D,
Snounou G, Renia L. 2011. Inhibitory effect of TNF-alpha on malaria
pre-erythrocytic stage development: influence of host hepatocyte/parasite
combinations. PLoS One 6:e17464. doi:10.1371/journal.pone.0017464.
54. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner
DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky
J, Wittes J, Cohen J, Ballou WR. 2001. Efficacy of recombinant circum-
sporozoite protein vaccine regimens against experimental Plasmodium
falciparum malaria. J. Infect. Dis. 183:640–647.
55. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner
DG, Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U,
Delchambre M, Voss G, Dubois MC, Gasser RA, Jr, Dowler MG,
O’Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR. 2007. A phase I/IIa
safety, immunogenicity, and efficacy bridging randomized study of a two-
dose regimen of liquid and lyophilized formulations of the candidate ma-
laria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25:5359–
5366.
56. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang
T, Gould J, Dubois Jongert M-CE, Vansadia P, Carter T, Njuguna P,
Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ,
Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM,
Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P. 2011. Efficacy of
RTS,S/AS01E malaria vaccine and exploratory analysis on anti-
circumsporozoite antibody titres and protection in children aged 5-17
months in Kenya and Tanzania: a randomised controlled trial. Lancet
Infect. Dis. 11:102–109.
57. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. 2010.
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
Hum. Vaccin. 6:90–96.
58. Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett
JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF,
Polhemus ME, Yadava A. 2012. Evaluation of immune responses to a
Plasmodium vivax CSP-based recombinant protein vaccine candidate in
combination with second-generation adjuvants in mice. Vaccine 30:
3311–3319.
59. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM,
Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL,
Nussenzweig MC, Steinman RM, Seder RA. 2010. Poly(I:C) is an effec-
tive adjuvant for antibody andmulti-functional CD4 T cell responses to
Plasmodium falciparum circumsporozoite protein (CSP) andDEC-CSP
in non human primates. Vaccine 28:7256–7266.
60. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L,
Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R,
McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N,
Milligan PJ. 2005. Safety and immunogenicity of RTS,S/AS02A candidate
malaria vaccine in Gambian children. Vaccine 23:4148–4157.
61. Schwenk RJ, Richie TL. 2011. Protective immunity to pre-erythrocytic
stage malaria. Trends Parasitol. 27:306–314.
62. Rénia L, Marussig MS, Grillot D, Pied S, Corradin G, Miltgen F, Del
Giudice G, Mazier D. 1991. In vitro activity of CD4 and CD8 T
lymphocytes from mice immunized with a synthetic malaria peptide.
Proc. Natl. Acad. Sci. U. S. A. 88:7963–7967.
63. Singh B, Cabrera-Mora M, Jiang J, Moreno A. 2012. A hybrid multistage
protein vaccine induces protective immunity against murine malaria. In-
fect. Immun. 80:1491–1501.
64. Oliveira GA, Kumar KA, Calvo-Calle JM, Othoro C, Altszuler D,
Nussenzweig V, Nardin EH. 2008. Class II-restricted protective immu-
nity induced by malaria sporozoites. Infect. Immun. 76:1200–1206.
65. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins
WE, Nussenzweig RS, Nussenzweig V. 1986. Inhibition of development
of exoerythrocytic forms of malaria parasites by gamma-interferon. Sci-
ence 232:881–884.
66. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V,
Zavala F. 1989. Cloned cytotoxic T cells recognize an epitope in the cir-
cumsporozoite protein and protect against malaria. Nature 341:323–326.
67. Schmidt NW, Butler NS, Harty JT. 2009. CD8 T cell immunity to
Plasmodium permits generation of protective antibodies after repeated
sporozoite challenge. Vaccine 27:6103–6106.
68. Tough DF, Borrow P, Sprent J. 1996. Induction of bystander T cell
proliferation by viruses and type I interferon in vivo. Science 272:1947–
1950.
69. Kastenmüller K, Wille-Reece U, Lindsay RWB, Trager LR, Darrah PA,
Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, Kaplan DH,
Kastenmüller W, Germain RN, Seder RA. 2011. Protective T cell immu-
nity in mice following protein-TLR7/8 agonist-conjugate immunization
requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest.
121:1782–1796.
70. Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA,
Kester KE, Cummings JF, Burge JR, Voss G, Delchambre M, Garçon N,
Tang DB, Cohen JD, Heppner DG. 2006. Pre-clinical evaluation of new
adjuvant formulations to improve the immunogenicity of themalaria vac-
cine RTS,S/AS02A. Vaccine 24:6483–6492.
71. Stewart VA, Walsh DS, McGrath SM, Kester KE, Cummings JF, Voss G,
Delchambre M, Garçon N, Cohen JD, Heppner DG. 2006. Cutaneous
delayed-type hypersensitivity (DTH) in a multi-formulation comparator
trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus
macaques. Vaccine 24:6493–6502.
Kastenmüller et al.



































































































5 7 9 16 18 31pre 0





























Supplementary Figure 1: 
Rhesus macaques were immunized with 100µg of CSP1 protein mixed with 
1mg of poly-ICLC. A total volume of 1ml was injected s.c. in the deltoid 
area of the upper arm. For boosting, the opposite arm was used. NHPs were 
immunized at weeks 0, 5 and 16. At indicated time-points after 
immunizations blood was collected and PBMCs were used for stimulation 
for ICS. Serum was also collected at indicated time-points to determine 
antibody titers. Frequency of CSP-specific IFN-γ-, IL-2- or TNFα- 
producing CD4+ T cells in PBMCs collected at peak (two weeks) and 
memory (15 weeks) after two (A) or three (B) immunizations.  Relative 
proportion of each individual combination of IFN-γ-, IL-2-, or TNFα-
producing cells in PBMCs collected at peak (two weeks) and memory (15 
weeks) after two (C) or three (D) immunizations. (E and F) CSP-specific 
IgG antibody titers. 	  
	  Supplementary Table 1: 
	  	  	  
Supplementary Table 1: Antibodies in serum from monkeys that received three 
immunizations with CSP1 and poly-ICLC adjuvant showed a strong binding 
capacity to sporozoites in vitro. Serum was collected at indicated time-points and 
IFA was performed as described in Table 1. +++ very good binding, ++ good binding, 
+ weak binding, - no binding. 	  	  	  	  
FLUORESCENT INTENSITY BY DILUTION 
TIME-POINT 1:100	   1:300	   1:900	   1:2700	   1:8100	   1:24300	  
PRE -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  2	  weeks	  after	  2	  immunizations	   ++	   ++	   ++	   +	   -­‐	   -­‐	  2	  weeks	  after	  3	  immunizations	   +++	   +++	   ++	   +	   +/-­‐	   +/-­‐	  15	  weeks	  after	  2	  immunizations	   +	   +	   +/-­‐	   -­‐	   -­‐	   -­‐	  15	  weeks	  after	  3	  immunizations	   ++	   +	   +/-­‐	   +/-­‐	   -­‐	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